Elise Hardy

Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial

Juan P. Frías, Cristian Guja, Elise Hardy et al. · The Lancet Diabetes & Endocrinology · 2016 · 379 citations

Diabetes Management, Diabetes, Pharmacology +8

Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

Serge Jabbour, Elise Hardy, Jennifer Sugg et al. · Diabetes Care · 2013 · 279 citations

Modeling effects of <scp>SGLT</scp>‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

Julia Dziuba, Peter Alperin, J. Racketa et al. · Diabetes Obesity and Metabolism · 2014 · 96 citations

Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial

Serge Jabbour, Juan P. Frías, Elise Hardy et al. · Diabetes Care · 2018 · 94 citations · Full text

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study

Cristian Guja, Juan P. Frías, Anikó Somogyi et al. · Diabetes Obesity and Metabolism · 2018 · 75 citations · Full text